secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000449
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones
--------------------------------------------------------------------------------

- Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.
- Preliminary cash, cash equivalents and investments as of Dec 31, 2022: approximately $79M (unaudited).
- Pediatric CAH trial amended: study length increased to 12 weeks plus 2-year open-label extension; age lowered to 2 years.
- Additional data to be collected: PK at 50mg and 200mg doses, A4 reduction, GC reduction, and 12-week safety data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/0000950170-23-000449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/sprb-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer